-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$20.33171.43% Upside
Larimar Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Larimar Therapeutics, Inc.?
Larimar Therapeutics, Inc. has been rated by research analysts at Citigroup, Wedbush, Leerink Partners in the past 90 days.